Business Wire

NV-GSMA

7.1.2020 18:02:07 CET | Business Wire | Press release

Share
GSMA Intelligence: US and European Consumers Cautious on Move to 5G Devices, China and Korea Set to Lead Early Adoption

The smartphone will remain the dominant consumer device into the new decade, but the arrival of 5G will not guarantee a surge in device upgrades, according to new GSMA Intelligence research. A new report, The Future of Devices , published at the Consumer Electronics Show (CES) 2020 in Las Vegas today, provides a wealth of insight on consumer technology adoption trends over the coming years, including the outlook for smartphones, smart speakers, wearables and other emerging categories.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005796/en/

Based on the results of GSMA Intelligence’s 2019 Consumer Survey, the report found that smartphone ownership among adults in most high- and middle-income countries is at 85-95 per cent. However, only 30-40 per cent of survey respondents in significant markets such as the US, Europe and Australia said the arrival of 5G is likely to result in a smartphone upgrade in the short term. By contrast, markets such as China and South Korea will be early adopters; nearly 50 per cent of Chinese consumers say they will buy a 5G phone as soon as they are available.

“The device ecosystem will be critical in shaping the trajectory of 5G adoption,” said Peter Jarich, Head of GSMA Intelligence. “However, it’s a mistake to believe that consumers in every market will look at 5G upgrades in the same way. Operators and device manufacturers will need to understand consumer demand on a granular level if they hope to make the most of the 5G opportunity.”

5G

Mixed picture for smart home and wearables

Fragmentation and a lack of compatibility between manufacturers hamper the adoption of smart home devices. However, this segment is being boosted by the growing popularity of smart speakers, such as Amazon’s Echo devices, which are increasingly acting as a single control point within the home. Smart speakers were the fastest moving category in the 2019 survey, now owned by 21 per cent of households, up ten percentage points over the previous year. Speakers have become a key battleground in the broader development of AI. Amazon and Google are furthest ahead, but both face the challenge of getting customers to go beyond basic functionality to higher-value tasks such as purchasing goods.

Meanwhile, the adoption rates for fitness trackers and smartwatches also picked up in 2019, and are now owned by 21 per cent and 10 per cent of adults, respectively. Millennials show the most substantial ownership rates of these devices, being more tech-savvy than older generations and also benefitting from an employer or insurance-based subsidies. However, the report notes that connected health devices continue to be sorely underrepresented among older populations. Missing older people is a missed opportunity for tech companies and governments, given that such devices can facilitate remote monitoring for a range of conditions, reducing the volume of in-person consultations and the strain on national healthcare systems.

The 2020 edition of The Future of Devices report is available to accredited members of the press on request. This report is based on GSMA Intelligence’s 2019 Consumer Survey, which surveyed 38,000 respondents across 36 key markets, using a blend of online and face-to-face sampling methodologies.

GSMA Intelligence @ #CES2020

GSMA Intelligence will be hosting a seminar dedicated to IoT at the MGM Grand in Las Vegas during CES. During this session, GSMA Intelligence will feature its latest forecasts and expectations for both consumer and enterprise IoT.

Our senior analysts will be available on-site for one-to-one media interviews during the week. We can provide expert commentary across a range of industry topics and discuss all the key announcements and developments. Please contact us at: media@gsmaintelligence.com

-ENDS-

About the GSMA

The GSMA represents the interests of mobile operators worldwide, uniting more than 750 operators and nearly 400 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces the industry-leading MWC events held annually in Barcelona, Los Angeles and Shanghai, as well as the Mobile 360 Series of regional conferences.

For more information, please visit the GSMA corporate website at www.gsma.com . Follow the GSMA on Twitter: @GSMA .

Contact:

For the GSMA: GSMA Press Office Isobel Moseley pressoffice@gsma.com

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release

Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604

Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release

Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S

Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release

Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o

U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release

TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica

European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye